EUVIMEDEUVIMED entdecken
Crossref

Impact of Zinc Supplementation and Topical Clobetasol on the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction: The ZINCLO-HAND Study

Orhun Akdogan iD, Enes Yesilbas iD, Mesut Yılmaz iD, Fatma Keskin Uzundere iD, Ahmet Oruc iD, Ender Eren Ozcelik, Gorkem Turhan iD, Mehmet Kayaalp iD, Ilknur Deliktas Onur iD, Haydar Temizyurek, Yasemin Evlendi, Okan Avcı iD und 20 weitere

JCO Oncology Practice · 04.11.2026

DOI: 10.1200/op-26-00226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 04.11.2026. Verfasst von Orhun Akdogan und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Regorafenib-induced hand-foot skin reaction (HFSR) is a common dose-limiting toxicity. We evaluated whether prophylaxis with oral zinc plus topical clobetasol is associated with lower clinically significant HFSR compared with either strategy alone.

Methods

ZINCLO-HAND was a prospective, multicenter, pragmatic, nonrandomized comparative study across 13 oncology centers in Türkiye. Adults initiating regorafenib were managed at physician discretion with oral zinc, topical clobetasol propionate 0.05%, or the combination for 8 weeks. The primary end point was grade ≥2 HFSR within the prophylaxis period. Secondary end points included grade 3 HFSR, treatment modification, relative dose intensity, and patient-reported outcomes.

Results

Of 179 enrolled patients, 156 were evaluable: zinc, n = 49; clobetasol, n = 52; combination, n = 55. Grade ≥2 HFSR occurred in 38.8%, 38.5%, and 16.4% of patients, respectively ( P = .016). In multivariable logistic regression adjusted for age, Eastern Cooperative Oncology Group performance status, tumor type, and initial regorafenib dose intensity, zinc monotherapy (adjusted odds ratio [OR], 3.37 [95% CI, 1.30 to 8.71]; P = .012) and clobetasol monotherapy (adjusted OR, 3.15 [95% CI, 1.26 to 7.88]; P = .014) were associated with higher odds of grade ≥2 HFSR versus combination prophylaxis. Median relative dose intensity was comparable across groups. HFSR-attributable treatment modification occurred in 30.6%, 28.8%, and 12.7% of patients, respectively.

Conclusion

In this nonrandomized prospective cohort, zinc plus topical clobetasol was associated with lower clinically significant regorafenib-induced HFSR and fewer HFSR-attributable treatment modifications. These findings support consideration of combination prophylaxis in routine practice and warrant randomized confirmation.

Autor:innen und Institutionen

  • Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.
  • Department of Medical Oncology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
  • Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey.
  • Department of Medical Oncology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey.
  • Department of Medical Oncology, Bursa Uludağ University Faculty of Medicine, Bursa, Turkey.

ORCID-Profile: Orhun Akdogan, Enes Yesilbas, Mesut Yılmaz, Fatma Keskin Uzundere, Ahmet Oruc, Gorkem Turhan, Mehmet Kayaalp, Ilknur Deliktas Onur, Okan Avcı, Mahmut Kara, Galip Can Uyar, Hasibe Bilge Gür, Kadriye Baskurt, Ramazan Cosar, Cengiz Karacin, Atila Yıldırım, Ahmet Bilgehan Sahin, Ahmet Ozet, Mehmet Artac, Nuriye Ozdemir, Osman Sutcuoglu

Zitieren

APA

Akdogan, O., Yesilbas, E., Yılmaz, M., Keskin Uzundere, F., Oruc, A., Ozcelik, E. E., Turhan, G., Kayaalp, M., Deliktas Onur, I., Temizyurek, H., Evlendi, Y., Avcı, O., Kara, M., Uyar, G. C., Gür, H. B., Coskun, U., Baskurt, K., Cetin, F., Uner, A., …, & Sutcuoglu, O. (2026). Impact of Zinc Supplementation and Topical Clobetasol on the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction: The ZINCLO-HAND Study. JCO Oncology Practice. https://doi.org/10.1200/op-26-00226

Vancouver

Akdogan O, Yesilbas E, Yılmaz M, Keskin Uzundere F, Oruc A, Ozcelik EE, et al. Impact of Zinc Supplementation and Topical Clobetasol on the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction: The ZINCLO-HAND Study. JCO Oncology Practice. 2026. doi:10.1200/op-26-00226

BibTeX
@article{Akdogan2026,
  author = {Akdogan, Orhun and Yesilbas, Enes and Yılmaz, Mesut and Keskin Uzundere, Fatma and Oruc, Ahmet and Ozcelik, Ender Eren and Turhan, Gorkem and Kayaalp, Mehmet and Deliktas Onur, Ilknur and Temizyurek, Haydar and Evlendi, Yasemin and Avcı, Okan and Kara, Mahmut and Uyar, Galip Can and Gür, Hasibe Bilge and Coskun, Ugur and Baskurt, Kadriye and Cetin, Fatma and Uner, Aytug and Cosar, Ramazan and Karacin, Cengiz and Utkan, Gungor and Yıldırım, Atila and Sahin, Ahmet Bilgehan and Ozet, Ahmet and Artac, Mehmet and Kaplan, Muhammed Ali and Bir Yucel, Kadriye and Ozdemir, Nuriye and Dizdar, Omer and Yazıcı, Ozan and Sutcuoglu, Osman},
  title = {Impact of Zinc Supplementation and Topical Clobetasol on the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction: The ZINCLO-HAND Study},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-26-00226}
}
Kostenlos starten →